Abstract:Background Targeted T-cell therapy has emerged as a promising strategy for the treatment of hematological malignancies. However, its application to solid tumors presents significant challenges due to the limited accessibility and heterogeneity. Localized delivery of tumor-specific T-cells using biomaterials has shown promise, however, procedures required for genetic modification and generation of a sufficient number of tumor-specific T-cells ex vivo remain major obstacles due to cost and time constraints. Methods Polyethylene glycol (PEG)-based three-dimensional (3D) scaffolds were developed and conjugated with positively charged poly-L-lysine (PLL) using carbamide chemistry for efficient loading of lentiviruses (LVs) carrying tumor antigen-specific T-cell receptors (TCRs). The physical and biological properties of the scaffold were extensively characterized. Further, the scaffold loaded with OVA-TCR LVs was implanted in B16F10 cells expressing ovalbumin (B16-OVA) tumor model to evaluate the anti-tumor response and the presence of transduced T-cells. Results Our findings demonstrate that the scaffolds do not induce any systemic inflammation upon subcutaneous implantation and effectively recruit T-cells to the site. In B16-OVA melanoma tumor-bearing mice, the scaffolds efficiently transduce host T-cells with OVA-specific TCRs. These genetically modified T-cells exhibit homing capability towards the tumor and secondary lymphoid organs, resulting in a significant reduction of tumor size and systemic increase in anti-tumor cytokines. Immune cell profiling revealed a significantly high percentage of transduced T-cells and a notable reduction in suppressor immune cells within the tumors of mice implanted with these scaffolds. Conclusion Our scaffold-based T-cell therapy presents an innovative in situ localized approach for programming T-cells to target solid tumors. This approach offers a viable alternative to in vitro manipulation of T-cells, circumventing the need for large-scale in vitro generation and culture of tumor-specific T-cells. It offers an off-the-shelf alternative that facilitates the use of host cells instead of allogeneic cells, thereby, overcoming a major hurdle.

Spiny Pollen-Based Antigen-Presenting Clusters for Promoting T Cells Expansion

Antigen‐Presenting Hybrid Colloidal Crystal Clusters for Promoting T cells Expansion

Biomimetic Dendritic Polymeric Microspheres Induce Enhanced T Cell Activation and Expansion for Adoptive Tumor Immunotherapy

Biomimetic Cascade-Released Hydrogel Scaffolds from Microfluidics for Efficient T Cell Recruitment and Expansion

Promoting the Activation of T Cells with Glycopolymer-Modified Dendritic Cells by Enhancing Cell Interactions.

Optimization of polydimethylsiloxane (PDMS) surface chemical modification and formulation for improved T cell activation and expansion

Antigen-specific T Cell Activation Through Targeted Delivery of In-Situ Generated Antigen and Calcium Ionophore to Enhance Antitumor Immunotherapy.

In Situ Genetic Engineering of Host T-cells Based on Acellular Scaffold Strategy: a Big but Also Small Step for Solid Tumor Immunotherapy

Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via An Injectable Hydrogel with A Supramolecular Binding Capability for Cancer Immunotherapy

Microfluidic-based preparation of artificial antigen-presenting gel droplets for integrated and minimalistic adoptive cell therapy strategies

Artificial Antigen‐presenting Immunomagnetic Beads for Better Enrichment and Expansion of T Lymphocytes from Peripheral Blood Mononuclear Cells

Pollen-Mimetic Metal–Organic Frameworks with Tunable Spike-Like Nanostructures That Promote Cell Interactions to Improve Antigen-Specific Humoral Immunity

Human cell-based artificial antigen-presenting cells for cancer immunotherapy

Nanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing

A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy

Cancer Therapy: Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen‐Presenting Systems by Intracellular Hydrogelation (Adv. Mater. 30/2021)

Generation of Antitumor T Cells for Adoptive Cell Therapy with Artificial Antigen Presenting Cells.

A strong CD8<SUP>+</SUP> T cell-stimulating supramolecular hydrogel

In Vivo Stimulation of Therapeutic Antigen‐Specific T Cells in an Artificial Lymph Node Matrix

Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen‐Presenting Systems by Intracellular Hydrogelation

T Cell Stimulation and Expansion by SunTag-based Clustering of Anti-Cd3/cd28 Scfv.